IVD Firm Caris Life Sciences Files for Nasdaq IPO, Aims to Raise $423.5M

Reprint#IVD Tool Person

Source: MedtechDive

Precision medicine company Caris Life Sciences announced on Monday plans to go public through an initial public offering (IPO).Raise up to $423.5 million (approximately 3.045 billion yuan) in funds.

Caris, headquartered in Irving, Texas, plans to go public on the Nasdaq under the ticker symbol “CAI”.Proposed issuance of 23.5 million ordinary shares, priced between $16 and $18 per share。

Caris focuses on major disease areas such as cancer. Its molecular profiling platform, combined with artificial intelligence and machine learning algorithms, covers a range of services including early detection, diagnosis, treatment monitoring, targeted therapy selection, and new drug development.

According to the company's securities filings, Caris Life Sciences' revenue for the first quarter of 2025 increased by approximately 50% year-over-year to reach $120.9 million, primarily driven by the growth of its molecular profiling services.

In November 2024, the company received FDA approval in the United States for its companion diagnostic product "MI Cancer Seek," which can be used to identify cancer patients who may benefit from targeted therapy.

Caris Life Sciences, founded in 2008, disclosed in documents that it has identified approximately 915,000 unique pathogenic mutations to date, of which only about 17,000 are known mutations in existing databases.

"We can now identify circulating pathogenic mutations within individuals and design fully personalized precision treatment plans accordingly," said David Dean Halbert, founder and CEO of Caris, in the document. "We believe this will provide doctors with an unprecedented opportunity to intervene at the earliest stages of disease, effectively preventing the occurrence of various chronic conditions."

In April this year, Caris completed a private financing round of $168 million, bringing the company's total financing to $1.86 billion since 2018.

Currently, Caris is one of the few healthcare technology companies exploring an IPO. As signs of a market recovery emerge, medical device supplier Medline has also indicated its potential to go public, while Medtronic plans to spin off its diabetes business into a standalone company, possibly through an IPO.

Add Lao Ji to the IVD group

Statement:This article only represents the author's viewpoint and does not reflect the platform's position.If the reprint involves copyright and other issues, please contact us as soon as possible. We will correct or delete it in the first instance. Thank you!